Scholarlink

Purpose <p>We evaluated the postoperative outcomes of patients with progressive disease after systemic chemotherapy compared with those with controlled disease.</p> Methods <p>This retrospective study analyzed patients from the Colorectal Cancer Liver Metastasis Database, compiled by the Joint Committee of Liver Metastases Survey from Colorectal Cancer. Patients who received chemotherapy were categorized into complete response, partial response, stable disease, and progressive disease groups and further subdivided into resected and non-resected subgroups. Survival outcomes and prognostic factors were evaluated.</p> Results <p>The number of patients in the complete response/partial response, stable disease, and progressive disease groups was 867, 550, and 195, respectively. Among the progressive disease group, 111 patients (57%) underwent hepatectomy. Their postoperative 5&#xa0;year overall survival rate was 42.7%, which was significantly lower than that of the resected-complete response/partial response (62.0%, <i>p</i>&lt;0.001) and resected-stable disease groups (55.5%; <i>p</i>&lt;0.001). However, overall survival from the date of colorectal liver metastases diagnosis of the resected-progressive disease group was better than that of the non-resected-partial response group (5&#xa0;year, 46.5% vs 11.4%, <i>p</i>&lt;0.001). Multivariate analysis performed on the resected-progressive disease group revealed preoperative carcinoembryonic antigen (CEA) ≥100 ng/mL and metachronous colorectal liver metastases as independent predictors of poor overall survival.</p> Conclusions <p>Although progressive disease after chemotherapy generally indicated poor prognosis, it should not be an absolute contraindication for hepatectomy. Preoperative CEA ≥100 ng/mL and metachronous colorectal liver metastases may identify a higher-risk subset and should be considered when determining surgical indications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatectomy After Progressive Disease Following Chemotherapy for Colorectal Liver Metastases: A Japanese Nationwide Cohort Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Kazuki Kobayashi,
  • Yoji Kishi,
  • Naoto Yonamine,
  • Takazumi Tsunenari,
  • Mikiya Takao,
  • Takahiro Einama,
  • Hironori Tsujimoto,
  • Hideki Ueno,
  • Hirotoshi Kobayashi,
  • Toru Beppu,
  • Megumi Ishiguro,
  • Kiyoshi Hasegawa,
  • Kazushige Kawai

摘要

Purpose

We evaluated the postoperative outcomes of patients with progressive disease after systemic chemotherapy compared with those with controlled disease.

Methods

This retrospective study analyzed patients from the Colorectal Cancer Liver Metastasis Database, compiled by the Joint Committee of Liver Metastases Survey from Colorectal Cancer. Patients who received chemotherapy were categorized into complete response, partial response, stable disease, and progressive disease groups and further subdivided into resected and non-resected subgroups. Survival outcomes and prognostic factors were evaluated.

Results

The number of patients in the complete response/partial response, stable disease, and progressive disease groups was 867, 550, and 195, respectively. Among the progressive disease group, 111 patients (57%) underwent hepatectomy. Their postoperative 5 year overall survival rate was 42.7%, which was significantly lower than that of the resected-complete response/partial response (62.0%, p<0.001) and resected-stable disease groups (55.5%; p<0.001). However, overall survival from the date of colorectal liver metastases diagnosis of the resected-progressive disease group was better than that of the non-resected-partial response group (5 year, 46.5% vs 11.4%, p<0.001). Multivariate analysis performed on the resected-progressive disease group revealed preoperative carcinoembryonic antigen (CEA) ≥100 ng/mL and metachronous colorectal liver metastases as independent predictors of poor overall survival.

Conclusions

Although progressive disease after chemotherapy generally indicated poor prognosis, it should not be an absolute contraindication for hepatectomy. Preoperative CEA ≥100 ng/mL and metachronous colorectal liver metastases may identify a higher-risk subset and should be considered when determining surgical indications.